Compile Data Set for Download or QSAR
Report error Found 56 Enz. Inhib. hit(s) with all data for entry = 11337
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608356BDBM608356(US11691989, Compound 14 | US11691989, Compound 15 ...)
Affinity DataIC50: 2nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608352BDBM608352(US11691989, Compound 10 | (Z)-15-chloro-13,25,61-t...)
Affinity DataIC50: 4nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608391BDBM608391(US11691989, Compound 47 | (Z)-15-chloro-13,21,25,6...)
Affinity DataIC50: 5nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608376BDBM608376(US11691989, Compound 32 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 5nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608393BDBM608393(US11691989, Compound 49 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 5nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 333146BDBM333146(US10196404, Example 1 | Compound I | US10196404, E...)
Affinity DataIC50: 7nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608233BDBM608233(US11691989, Compound 1 | (Z)-15-chloro-13,61-dimet...)
Affinity DataIC50: 7nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608382BDBM608382(US11691989, Compound 38 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 7nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608390BDBM608390(US11691989, Compound 46 | (Z)-15-chloro-13,21,25,6...)
Affinity DataIC50: 8nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608383BDBM608383(US11691989, Compound 39 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 9nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608347BDBM608347(US11691989, Compound 5 | US11691989, Compound 6 | ...)
Affinity DataIC50: 9nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608361BDBM608361(US11691989, Compound 19 | (Z)-15-chloro-13,96-difl...)
Affinity DataIC50: 10nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608363BDBM608363(US11691989, Compound 21 | (Z)-15,96-difluoro-13,21...)
Affinity DataIC50: 10nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608392BDBM608392(US11691989, Compound 48 | (Z)-15-chloro-13,21,23,6...)
Affinity DataIC50: 12nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608384BDBM608384(US11691989, Compound 40 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 13nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608370BDBM608370(US11691989, Compound 26 | Z)-15-chloro-13,23,61-tr...)
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608351BDBM608351(US11691989, Compound 9 | (Z)-13,15-dichloro-21,25,...)
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608372BDBM608372(US11691989, Compound 28 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608345BDBM608345(US11691989, Compound 3 | Z)-15-chloro-96-fluoro-13...)
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608340BDBM608340(US11691989, Compound 2 | Z)-15-chloro-96-fluoro-13...)
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608346BDBM608346(US11691989, Compound 4 | (Z)-15-chloro-96-fluoro-1...)
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608362BDBM608362(US11691989, Compound 20 | (Z)-15-cyano-96-fluoro-1...)
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608371BDBM608371(US11691989, Compound 27 | (Z)-15-chloro-21-(2-meth...)
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608353BDBM608353(US11691989, Compound 11 | (Z)-15-chloro-21-(2-meth...)
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608368BDBM608368(US11691989, Compound 24 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608379BDBM608379(US11691989, Compound 35 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608360BDBM608360(US11691989, Compound 18 | (Z)-15-chloro-25-(difluo...)
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608359BDBM608359(US11691989, Compound 17 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608364BDBM608364(US11691989, Compound 22 | (Z)-96-fluoro-13,15,21,2...)
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608375BDBM608375(US11691989, Compound 31 | (Z)-15-chloro-4-(cyclopr...)
Affinity DataIC50: 16nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608389BDBM608389(US11691989, Compound 45 | (Z)-15-chloro-25-(difluo...)
Affinity DataIC50: 16nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608365BDBM608365(US11691989, Compound 23 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 16nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608385BDBM608385(US11691989, Compound 41 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 17nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608374BDBM608374(US11691989, Compound 30 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 17nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608395BDBM608395(US11691989, Compound 51 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 17nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608347BDBM608347(US11691989, Compound 5 | US11691989, Compound 6 | ...)
Affinity DataIC50: 17nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608354BDBM608354(US11691989, Compound 12 | (Z)-13-(acetamidomethyl)...)
Affinity DataIC50: 18nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608356BDBM608356(US11691989, Compound 14 | US11691989, Compound 15 ...)
Affinity DataIC50: 19nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608355BDBM608355(US11691989, Compound 13 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 19nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608394BDBM608394(US11691989, Compound 50 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 20nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608369BDBM608369(US11691989, Compound 25 | (Z)-15-chloro-13-cyano-9...)
Affinity DataIC50: 21nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608350BDBM608350(US11691989, Compound 8 | (Z)-15-chloro-13-ethyl-21...)
Affinity DataIC50: 21nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608396BDBM608396(US11691989, Compound 52 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 21nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608387BDBM608387(US11691989, Compound 43 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 22nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608386BDBM608386(US11691989, Compound 42 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 22nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608388BDBM608388(US11691989, Compound 44 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 23nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608399BDBM608399(US11691989, Compound 55 | Z)-15-chloro-96-fluoro-1...)
Affinity DataIC50: 24nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608398BDBM608398(US11691989, Compound 54 | (Z)-15-chloro-4-(2-(dime...)
Affinity DataIC50: 27nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608380BDBM608380(US11691989, Compound 36 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 27nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandChemical structure of BindingDB Monomer ID 608381BDBM608381(US11691989, Compound 37 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 29nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
US Patent

Displayed 1 to 50 (of 56 total ) | Next | Last >>
Jump to: